Combinations with modulators of pnpla3 expression
AssigneeAstraZeneca AB
InventorDaniel LINDÉN
Life of this patent
Estimating the term…
Abstract
Provided are methods of treating a liver disease in a subject, comprising administering to the subject: i) an inhibitor of patatin like phospholipase domain containing 3 (PNPLA3) expression; and ii) an agonist of glucagon receptor and/or glucagon-like peptide-1 (GLP-1) receptor. Also provided pharmaceutical and kits comprising i) an inhibitor of PNPLA3 expression; and ii) an agonist of glucagon receptor and/or GLP-1 receptor.
Claims103
A method of treating a liver disease in a subject, comprising administering to the subject:
- i) an inhibitor of patatin like phospholipase domain containing 3 (PNPLA3) expression;
- and
- ii) an agonist of glucagon receptor and/or glucagon-like peptide-1 (GLP-1) receptor.
A method of reducing steatosis in the liver of a subject having a liver disease, comprising administering to the subject:
- i) an inhibitor of patatin like phospholipase domain containing 3 (PNPLA3) expression;
- and
- ii) an agonist of glucagon receptor and/or glucagon-like peptide-1 (GLP-1) receptor.
A method of reducing inflammation in the liver of a subject having a nonalcoholic fatty liver disease, comprising administering to the subject:
- i) an inhibitor of patatin like phospholipase domain containing 3 (PNPLA3) expression;
- and
- ii) an agonist of glucagon receptor and/or glucagon-like peptide-1 (GLP-1) receptor.
A method of reducing liver collagen in a subject having a liver disease, comprising administering to the subject:
- i) an inhibitor of patatin like phospholipase domain containing 3 (PNPLA3) expression;
- and
- ii) an agonist of glucagon receptor and/or glucagon-like peptide-1 (GLP-1) receptor.
A pharmaceutically acceptable composition comprising:
- i) an inhibitor of patatin like phospholipase domain containing 3 (PNPLA3) expression;
- ii) an agonist of glucagon receptor and/or glucagon-like peptide-1 (GLP-1) receptor;
- iii) at least one pharmaceutically acceptable excipient.
A kit comprising:
- i) an inhibitor of patatin like phospholipase domain containing 3 (PNPLA3) expression;
- and
- ii) an agonist of glucagon receptor and/or glucagon-like peptide-1 (GLP-1) receptor.
Dependencies are inferred from the claim text.